Late Breaking Abstract - Clinical efficacy of Tezepelumab in pre-selected non-Type 2 asthma patients

<bold>Introduction</bold> Stromal Lymphopoietin (TLSP) plays a role in the non-Type 2 (T2) asthma pathway, which makes this biomarker a target for the treatment. Blockade of TSLP reduces a broad spectrum of biomarkers and cytokines associated with airway inflammation. Tezepelumab is a monoclonal antibody (IgG2λ) directed against TSLP and prevents interaction with the heterodimeric TSLP receptor. Tezepelumab has a probable positive effect on exacerbation rate, lung function, and quality of life in patients with non-eosinophilic asthma. This is the first case series that highlights the clinical effect of tezepelumab in pre-well-defined non-T2 asthma patients following the Global Initiative for Asthma (GINA) guideline. <bold>Method</bold> Patients were treated (per protocol) with 210 mg of Tezepelumab (subcutaneous) every 4 weeks for 6 months. During each visit (T0-T6), the patients received a lung function (FEV1) and 2 questionnaires; the Asthma Quality of Life Questionnaire (ACQ) and the Asthma Quality of Life Questionnaire (AQLQ). Medical ethical approval for this study was obtained (NL78940.100.21). <bold>Results</bold> All patients were females and aged between 18 to 68 years (Table 1). The BMI ranged from 19.90 to 39.80 kg/mm2. After treatment with Tezepelumab, the FEV1 improved for 6 out of the 8 patients and the ACQ- and AQLQ-score improved for 5 and 6 out of the 8 patients, respectively (Figure 1). <bold>Conclusion</bold> This is the first case series demonstrating that patients with non-T2 asthma benefit from treatment with Tezepelumab regarding lung function, ACQ, and AQLQ. However, an extensive placebo-controlled trial is needed to confirm the clinically beneficial effects of Tezepelumab in non-T2 asthma patients.